ArticleCureus2025
Association of Apolipoprotein E (APOE) Gene Polymorphism With Age-Related Macular Degeneration (AMD) in Indian Patients.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Age-related macular degeneration (AMD or ARMD; Online Mendelian Inheritance in Man (OMIM) #603075) is the degenerative disease of the retina that causes progressive impairment of central vision, leading to irreparable vision loss in older persons. Objective The objective was to investigate the association between apolipoprotein E (APOE) gene polymorphism and AMD in Indian patients. Materials and methods Genotyping for APOEvariants was performed in 121 AMD patients and 100 healthy controls using a polymerase chain reaction and restriction fragment length polymorphism (PCR-RFLP) method, followed by sequencing. Genotype and allele were analyzed using the allele counting method. P-value < 0.05 was considered statistically significant. Results The E3/E3 genotype has a frequency of 76/100 (76%) in controls and 97 (80%) in AMD. The frequency of the heterozygous E2/E2 genotype was 19 (19%) in controls and eight (6.6%) in AMD, and the variant E4/E4 genotype was found in one control (1%) and in one AMD case (1%). Some protective effect of the E2/E2 heterozygous genotype is seen (OR = 0.30;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.